APA (7th ed.) Citation

Besse, B., Springfeld, C., Baik, C., Hervieu, A., Solomon, B., Moreno, V., . . . Drilon, A. (2022). 209 (PB089) - Update from the ongoing phase 1/2 registrational trial of repotrectinib: Results in TKI-naïve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1). European Journal of Cancer, 174, S75. https://doi.org/10.1016/S0959-8049(22)01000-0

Chicago Style (17th ed.) Citation

Besse, B., et al. "209 (PB089) - Update from the Ongoing Phase 1/2 Registrational Trial of Repotrectinib: Results in TKI-naïve and TKI-pretreated Patients with NTRK Fusion-positive Advanced Solid Tumors (TRIDENT-1)." European Journal of Cancer 174 (2022): S75. https://doi.org/10.1016/S0959-8049(22)01000-0.

MLA (9th ed.) Citation

Besse, B., et al. "209 (PB089) - Update from the Ongoing Phase 1/2 Registrational Trial of Repotrectinib: Results in TKI-naïve and TKI-pretreated Patients with NTRK Fusion-positive Advanced Solid Tumors (TRIDENT-1)." European Journal of Cancer, vol. 174, 2022, p. S75, https://doi.org/10.1016/S0959-8049(22)01000-0.